These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Dyslipidemias and the primary prevention of cardiovascular disease: analysis of the FAMUS primary care register. Xhignesse M; Laplante P; Niyonsenga T; Courteau J; Grant AM Can J Cardiol; 2000 Jul; 16(7):879-85. PubMed ID: 10934306 [TBL] [Abstract][Full Text] [Related]
3. Clinical practice guidelines for the management of dyslipidemia. Nichols N Can J Cardiovasc Nurs; 2004; 14(2):7-10. PubMed ID: 15230023 [TBL] [Abstract][Full Text] [Related]
5. Hyperlipidemia management in patients with cardiovascular and cerebrovascular disease. J Fla Med Assoc; 1998 Apr; 85(1):26-8. PubMed ID: 9782725 [No Abstract] [Full Text] [Related]
6. [Primary prevention of cardiovascular diseases by lowering lipids]. Klose G Internist (Berl); 1997 Jun; 38(6):615-6. PubMed ID: 9265009 [No Abstract] [Full Text] [Related]
7. [Diabetic dyslipidemia: which target levels and treatment options exist for diabetics?]. Broedl UC; Lehrke M; Parhofer KG MMW Fortschr Med; 2008 Jun; 150(25):41-3. PubMed ID: 18705054 [No Abstract] [Full Text] [Related]
8. Update on statins and other lipid-lowering drugs. Miller CA Geriatr Nurs; 2001; 22(5):276-7. PubMed ID: 11606910 [No Abstract] [Full Text] [Related]
9. Lipid management in patients with diabetes mellitus. Brown AS Am J Cardiol; 2005 Aug; 96(4A):26E-32E. PubMed ID: 16098840 [TBL] [Abstract][Full Text] [Related]
10. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Robson J Heart; 2008 Oct; 94(10):1331-2. PubMed ID: 18701534 [No Abstract] [Full Text] [Related]
11. Time for results: a better way to reduce cardiovascular risk. Mola A; Lloyd M Adv Nurse Pract; 2002 Apr; 10(4):34-41; quiz 42-3. PubMed ID: 12418348 [No Abstract] [Full Text] [Related]
12. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Graham I; Atar D; Borch-Johnsen K; Boysen G; Burell G; Cifkova R; Dallongeville J; De Backer G; Ebrahim S; Gjelsvik B; Herrmann-Lingen C; Hoes A; Humphries S; Knapton M; Perk J; Priori SG; Pyorala K; Reiner Z; Ruilope L; Sans-Menendez S; Op Reimer WS; Weissberg P; Wood D; Yarnell J; Zamorano JL; Walma E; Fitzgerald T; Cooney MT; Dudina A; Vahanian A; Camm J; De Caterina R; Dean V; Dickstein K; Funck-Brentano C; Filippatos G; Hellemans I; Kristensen SD; McGregor K; Sechtem U; Silber S; Tendera M; Widimsky P; Zamorano JL; Altiner A; Bonora E; Durrington PN; Fagard R; Giampaoli S; Hemingway H; Hakansson J; Kjeldsen SE; Larsen ML; Mancia G; Manolis AJ; Orth-Gomer K; Pedersen T; Rayner M; Ryden L; Sammut M; Schneiderman N; Stalenhoef AF; Tokgözoglu L; Wiklund O; Zampelas A; ; ; ; ; ; ; ; ; ; Eur J Cardiovasc Prev Rehabil; 2007 Sep; 14 Suppl 2():E1-40. PubMed ID: 17726406 [No Abstract] [Full Text] [Related]
13. [Pharmacologic interventions in primary prevention: lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents]. Auer J; Berent R; Weber T; Porodko M; Mayr H; Maurer E; Eber B Wien Med Wochenschr; 2001; 151(1-2):13-7. PubMed ID: 11234591 [TBL] [Abstract][Full Text] [Related]
14. [Strategies for cardiovascular prevention in women]. Leuzzi C; Modena MG G Ital Cardiol (Rome); 2010 May; 11(5 Suppl 3):93S-96S. PubMed ID: 20879491 [No Abstract] [Full Text] [Related]
15. Taking risks: primary prevention of cardiovascular events. Vallance P N Z Med J; 2001 May; 114(1132):223-4. PubMed ID: 11453356 [No Abstract] [Full Text] [Related]
16. Demystifying good high-density lipoprotein from dysfunctional high-density lipoprotein. Drown DJ Prog Cardiovasc Nurs; 2008; 23(4):198-9. PubMed ID: 19067988 [No Abstract] [Full Text] [Related]
17. Clinical inquiries. What is the best strategy for monitoring the lipid-lowering effects of medical therapy used for the primary prevention of coronary artery disease (CAD)? Sherrod JP; Krist A J Fam Pract; 2001 Nov; 50(11):928. PubMed ID: 11711006 [No Abstract] [Full Text] [Related]
18. [Cardiovascular primary prevention must walk on both legs. Individual as well as public health measures are necessary]. Nilsson PM Lakartidningen; 2005 Mar 7-13; 102(10):783, 785; discussion 785. PubMed ID: 15839173 [No Abstract] [Full Text] [Related]